Abstract

Hexadentate tris(3,4-hydroxypyridinone) ligands (THP) complex Fe3+ at very low iron concentrations and their high affinities for oxophilic trivalent metal ions have led to their development for new applications as bifunctional chelators for the radiometal gallium-68 (68Ga). THP-peptide bioconjugates rapidly and quantitatively complex 68Ga at room temperature, neutral pH, and micromolar ligand concentrations, making them amenable to kit-based radiosynthesis of 68Ga PET radiopharmaceuticals. With the aim to produce an N-hydroxysuccinimide-(NHS)-THP reagent for kit-based 68Ga-labeling and PET imaging, THP-derivatives were designed and synthesized to exploit the advantages of NHS chemistry for coupling with peptides, proteins, and antibodies. The more stable five-carbon atoms linker product was selected for a proof-of-concept conjugation and radiolabeling study with an anti-programmed death ligand 1 (PD-L1) camelid single domain antibody (sdAb) under mild conditions and further evaluated for site-specific amide bond formation with a synthesized glucagon-like peptide-1 (GLP-1) targeting peptide using solid-phase synthesis. The obtained THP-GLP-1 conjugate was tested for its 68Ga chelating ability, demonstrating to be a promising candidate for the detection and monitoring of GLP-1 aberrant malignancies. The obtained sdAb-THP conjugate was radiolabeled with 68Ga under mild conditions, providing sufficient labeling yields after 5 min, demonstrating that the novel NHS-THP bifunctional chelator can be widely used to easily conjugate the THP moiety to different targeting molecules (e.g., antibodies, anticalins, or peptides) under mild conditions, paving the way to the synthesis of different imaging probes with all the advantages of THP radiochemistry.

Highlights

  • Radiometals are radioactive metal isotopes that can be exploited in medical diagnosis and cancer therapy

  • With the aim to produce a kit-based NHS-THP for effortless and efficient gallium labeling under physiological conditions, two THP-derivatives (6,7) were designed and synthesized for exploiting the advantages of NHS chemistry for the successful and biocompatible coupling with antibodies and proteins [20]

  • No major difference was observed in the mass spectra of the two conjugates: a peak corresponding to the native single domain antibody (sdAb) was observed, in the conjugated sample, a peak corresponding to the 1:1 conjugate 10 was detectable, demonstrating qualitatively the successful conjugation due to amide bond formation between the sdAb and the THP-NHS ligand under mild conditions

Read more

Summary

Introduction

Radiometals are radioactive metal isotopes that can be exploited in medical diagnosis and cancer therapy. To use these isotopes effectively for medical applications, the free radiometal ion—present in low concentrations—must be sequestered from aqueous solution using a chelating agent. When the targeting molecule, engineered with a chelator, is injected into a patient, it should deliver the radioactive isotope without radiometal loss and supply an in vivo site-specific radioactive source for imaging or therapy purpose. Biomedicines 2021, 9, 367 are constantly being developed. 68 Ga, 64 Cu, 86 Y, 89 Zr, and 44 Sc are some examples of radiometals that are currently used clinically for positron emission tomography (PET) Thanks to the wide range of generated and available radionuclides, it is currently possible to meticulously pick the specific nuclear properties that are needed for the specific application. 68 Ga, 64 Cu, 86 Y, 89 Zr, and 44 Sc are some examples of radiometals that are currently used clinically for positron emission tomography (PET)

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call